220
Participants
Start Date
June 21, 2019
Primary Completion Date
October 27, 2021
Study Completion Date
March 16, 2022
Letermovir
LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
Placebo
Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
Memorial Sloan Kettering Cancer Center ( Site 0164), New York
IRCCS Ospedale San Raffaele ( Site 0051), Milan
ASST Spedali Civili di Brescia ( Site 0052), Brescia
Duke University Medical Center ( Site 0169), Durham
University of Miami, Sylvester Comprehensive Cancer Center ( Site 0160), Miami
Hopital Saint Eloi ( Site 0031), Montpellier
Indiana Blood and Marrow Transplantation ( Site 0175), Indianapolis
Universitaetsklinikum Muenster ( Site 0043), Münster
Universitaetsklinik Koeln ( Site 0041), Cologne
Universitaetsklinikum Heidelberg-Medizinische Klinik V ( Site 0042), Heidelberg
Centre Hopitalier Lyon Sud ( Site 0039), Pierre-Bénite
CHU Hopital Saint Antoine ( Site 0036), Paris
The University of Texas MD Anderson Cancer Center ( Site 0154), Houston
Centre Hospitalier Universitaire Dupuytren ( Site 0182), Limoges
City of Hope National Medical Center ( Site 0158), Duarte
CHU Henri Mondor ( Site 0032), Créteil
Institut Gustave Roussy ( Site 0038), Villejuif
University of California Davis Medical Center ( Site 0156), Sacramento
Fred Hutchinson Cancer Research Center ( Site 0152), Seattle
Brigham & Women's Hospital ( Site 0161), Boston
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0174), Hackensack
Fondazione PTV Policlinico Tor Vergata ( Site 0054), Roma
Policlinico Umberto I ( Site 0056), Roma
Policlinico Universitario Agostino Gemelli ( Site 0055), Roma
Jichi Medical University Hospital ( Site 0123), Shimotsuke
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 0121), Hiroshima
National Hospital Organization Kumamoto Medical Center ( Site 0122), Kumamoto
Queen Elizabeth University Hospital [Glasgow, UK] ( Site 0096), Glasgow
1Kings College Hospital ( Site 0091), London
UCL Cancer Institute ( Site 0093), London
Manchester Royal Infirmary ( Site 0097), Manchester
Freeman Hospital Newcastle upon Tyne Foundation NHS Trust ( Site 0092), Newcastle upon Tyne
Merck Sharp & Dohme LLC
INDUSTRY